Why the study?
Does low-molecular-weight heparin improve outcomes in patients with advanced cancer and venous thromboembolism receiving palliative care?
Does low-molecular-weight heparin improve outcomes in patients with advanced cancer and venous thromboembolism receiving palliative care?
The use of continued anticoagulation for VTE for palliative purposes in advanced cancer remains controversial due to a lack of large randomized trials.
Individualized risk-benefit assessment remains essential for anticoagulation in palliative cancer VTE; leaves open LMWH efficacy without large RCTs.
Patients with cancer are at risk of developing venous thromboembolism ([VTE]; deep venous thrombosis, and pulmonary embolism). Although vitamin K antagonists had originally been used to treat VTE in these patients, low-molecular-weight heparins (LMWH) have been shown to be more effective and safe for patients with cancer-associated thrombosis. In cancer patients with advanced disease where curative therapy is no longer the intent of treatment, continued anticoagulation for VTE for palliative purposes continues to remain a controversial topic as no large randomized trials have been conducted to guide clinicians in this setting. This review summarizes the data available for treating VTE in cancer patients receiving palliative services.
No takes yet. Share an insight, caveat, or question.
Quy Tran (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: